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Edited by Varda RotterAbstract Telomerase activation is regulated by the expression
of human telomerase reverse transcriptase (hTERT) and is a
key step in the development of human cancers. Interferon-c
(IFN-c) signaling induces growth arrest in many tumors through
multiple regulatory mechanisms. The p27 tumor suppressor pro-
tein inhibits the formation of tumors through the induction of cell
cycle arrest and/or apoptosis. We demonstrate here that p27Kip1
inhibits hTERT mRNA expression and telomerase activity
through post-transcriptional up-regulation by IFN-c/IRF-1 sig-
naling. The ectopic expression of p27 suppressed hTERT expres-
sion and telomerase activity in human cervical cancer cell lines,
HeLa and HT3. Furthermore, hTERT promoter activity of
mouse embryonic ﬁbroblasts (MEFs) deﬁcient in p27 (p27/
MEFs) was signiﬁcantly higher than that of wild-type MEFs.
Overexpression of p27 suppressed hTERT promoter activity
and telomerase activity of p27/ MEFs. In addition p27
down-regulated E7 protein expression and in transiently trans-
fected HeLa cells, E7 increased hTERT promoter activity. In
conclusion, we propose that inhibition of the hTERT expression
and telomerase activity may be a novel tumor suppressor func-
tion of p27.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Telomerase, a highly specialized RNA-directed DNA poly-
merase, maintains telomere length by synthesizing hexameric
telomeric repeats [1]. Most cancer cells show elevated telome-
rase activity, whereas normal tissues have no detectable telo-Abbreviations: hTERT, human telomerase reverse transcriptase; IFN-
c, interferon c; IRF-1, interferon regulatory factor-1; CDK, cyclin-
dependent kinase; CDKI, CDK inhibitor; MEFs, mouse embryonic
ﬁbroblasts; HPV, human papillomavirus
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doi:10.1016/j.febslet.2005.01.005merase activity. This suggests that stable telomere length is
required for cellular immortalization and tumorigenesis [2].
As with the telomerase activity, human telomerase reverse
transcriptase (hTERT) expression is detected in most tumor
tissues (approximately 90%) but is not detectable in normal tis-
sues [2,3]. Ectopic expression of hTERT can restore telomerase
activity in many telomerase-negative cell types, thereby
immortalizing them [4,5]. Furthermore, expression of the dom-
inant-negative (D/N) hTERT or antisense against hTERT
eﬀectively inhibits telomerase activity in human cancer cells
forcing them either into apoptosis or to diﬀerentiate [6]. This
evidence strongly suggests that expression of hTERT is a
rate-limiting step in telomerase activity. Yet its transcriptional
regulatory mechanism of hTERT is poorly established
although intensive investigations have been performed to char-
acterize the core promoter region of hTERT and identify po-
tential transcriptional activators or inhibitors.
Previously, a novel anti-cancer mechanism of interferon c
(IFN-c)/interferon regulatory factor-1 (IRF-1) signaling that
down-regulates hTERT expression was suggested [7]. In an at-
tempt to identify the potential regulator(s) of the IFN-c/IRF-1
signaling involved in suppressing hTERT expression and
telomerase activity, we found that p27, a member of a
cyclin-dependent kinase inhibitor (CDKI) family, has potent
inhibitory eﬀects on hTERT expression in human cervical can-
cer cell lines. The conventional importance on the anti-mito-
genic role of p27 is through cell cycle arrest by binding to
cyclin-dependent kinases 2 (CDKs) and then suppressing
cyclin E/cdk2 complexes. Recently, new functional roles of
p27 have been suggested. Conﬂicting but important data has
shown that p27 might be involved in the apoptotic cell death
under certain conditions. For example, the adenoviral ectopic
expression of p27 results in apoptosis in human breast cancer
cells as well as in other cancer cell lines [8,9].
In previous studies, p27-deﬁcient mice showed increase
growth rate and body size, multiple organomegaly, and a high
incidence of pituitary tumors indicating its varied roles in con-
trolling growth and proliferation [10]. The roles of p27 in tu-
mor suppression have been proposed from Koﬀs group
where accelerated tumor development in Rb+/p27/ mice
was found compared to Rb+/p27+/+ mice [11]. They also
showed that p27 expression can be a strong prognostic indica-
tor in various types of cancer. Taken together, these studiesblished by Elsevier B.V. All rights reserved.
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through multiple mechanisms.
In order to determine if the tumor suppressor function of
p27 included suppression of telomerase, we examined the reg-
ulation of telomerase activity and hTERT mRNA expression
by IRF-1-induced p27 in human cervical cancer cell lines
and mouse embryonic ﬁbroblasts (MEFs) of wild and p27-deﬁ-
cient mice. In addition, the possible regulatory pathways of tel-
omerase activity by p27 were also examined.2. Results
2.1. IFN-c increases p27 protein level through IRF-1
In previous reports, we demonstrated that IFN-c down-reg-
ulates hTERT expression, which is mediated by IRF-1 [7].
Exploring further down stream of IFN-c/IRF-1 signaling,
p27 was uncovered as a possible inhibitory mediator of
hTERT expression. Human cervical cancer cell lines, HeLa
and HT-3, were incubated with 250 U/ml human IFN-c for
the indicated times. Signiﬁcantly increased p27 protein levels
were observed in both cell lines following incubation with
IFN-c at 48 h post-treatment (Fig. 1). Subsequently, the cells
were transfected with pcDNA-IRF-1 and incubated them for
the indicated times. As shown in Fig. 1, p27 protein was ele-
vated in a similar pattern to treatment of IFN-c. Consistent
with previous ﬁndings [12,13], we did not observe any changes
in the p27 mRNA level when treated with IFN-c as well as in
IRF-1 transfected cells, indicating post-transcriptional regula-
tion (data not shown). In order to investigate whether or not
p27 induction is mediated by IFN-c/IRF-1 signaling, primary
MEFs which were derived from mice deﬁcient in IRF-1 (IRF-
1/ MEFs) and wild-type (WT) mice were incubated with
250 U/ml of IFN-c. The cells were harvested at the times indi-
cated and subjected to immunoblot analysis. In contrast to the
WT MEFs in which IFN-c up-regulated the p27 levels (as in
cervical cancer cells), the p27 level of the IRF-1/ MEFs
was not changed by the IFN-c treatment (Fig. 1). These resultsFig. 1. Eﬀect of IFN-c or IRF-1 on the expression of p27. Human
cervical cancer cells, WT MEFs and p27-deﬁcient MEFs were treated
with IFN-c or transfected with pcDNA-IRF-1 for the indicated time
points. Western blot analysis was performed on total cell lysates
(20 lg) using anti-serum against p27.indicate that the up-regulation of the p27 level following the
IFN-c treatment is dependent on IRF-1.
2.2. p27 suppresses hTERT expression and telomerase activity
Next, we examined whether p27 suppressed hTERT expres-
sion and telomerase activity. As shown in Fig. 2A, telomerase
activity was strongly suppressed at 48 h in HeLa and HT-3
cells after p27 transfection. hTERT expression was also
markedly reduced by the introduction of p27 as determined
by reverse transcription (RT)-PCR. Signiﬁcant decreases in
hTERT mRNA level were observed at 18 h (HeLa cells) or
24 h (HT-3 cells) after transfection (Fig. 2C). To further ad-
dress whether or not p27 aﬀects hTERT transcription, the
cells were co-transfected with 2 lg of the 3996-bp hTERT
promoter reporter gene construct and various amounts of
Ad-p27 (0, 10, 20, 50, 100, 200 m.o.i.). The cells transiently
transfected with p27 showed suppressed hTERT promoter
activity in a dose-dependent manner in both cell lines (Fig.
2D). These results suggest that p27 plays a suppressive role
in hTERT expression and telomerase activity in human cervi-
cal cancer cells.
2.3. hTERT expression and telomerase activity in MEFs
genetically deﬁcient in p27
Primary MEFs genetically deﬁcient in p27 were used to con-
ﬁrm the suppressive function of p27Kip in hTERT expression.
As shown in Fig. 3A, the MEFs deﬁcient in p27 showed more
than 4 times higher hTERT promoter activity than the WT
MEFs indicating a signiﬁcantly higher level of basal hTERT
promoter activity in the p27/MEFs. Furthermore, hTERT
promoter activity was determined after transient transfection
of the p27 expression adenovirus to the p27/ MEFs. As ex-
pected, overexpression of p27 reduced reporter activity in a
dose-dependent manner (Fig. 3B) and down-regulated telome-
rase activity (Fig. 3C). However, IFN-c did not down-regulate
telomerase activity in p27/ MEFs (Fig. 3D). These results
conﬁrm that p27 is essential for the regulation of hTERT
expression.2.4. Down-regulation of the E7 protein level by p27 may be one
repression pathway of hTERT transcription
Overexpression of cdk2, cdk4, or cyclin D1 restores telome-
rase activity, proposed that released E2F-1 positively regu-
lates telomerase activity [14]. Cyclin A and E, well-known
proteins as being transcriptionally regulated by E2F-1, fol-
lowed by status of Rb phosphorylation, In order to explore
the possible mechanism by which cyclin inhibitory protein,
p27 regulates hTERT expression, we preferentially examined
the cyclin E, cyclin A, and cdk2 expression in the IFN-c trea-
ted cell lines. As expected, a signiﬁcant decrease in both cyclin
E and cyclin A levels was observed in HeLa cells. However, in
HT-3 cells, cyclin E level was not changed (Fig. 4A). The
time-dependent decrease in Cdk2 activity in both cell lines
was observed (Fig. 4B). Hypophosphorylated Rb functions
as a cell cycle repressor by interacting with E2F protein which
results in the inhibition of E2F-mediated gene transcription.
Functional Rb has also been reported to down-regulate telo-
merase activity. It was also found that transiently transfected
p27 down-regulated phosphorylated Rb protein levels in HT-
3 (Fig. 4C) and HeLa (data not shown). In order to determine
if E2F-1 serves as a transcriptional regulator, 2 lg of the
Fig. 2. Eﬀects of p27 on telomerase activity, hTERT levels and hTERT promoter activity on HeLa and HT-3 cells. Cells were transfected with
adenovirus vector, AdCMV-p27, for the indicated time points. Telomerase activity and hTERT expression were determined using TRAP assay (A)
and RT-PCR (B). Relative telomerase activity (d) and hTERT level (j) were indicated (C), as described in Section 4. Data shown are representative
of three independent experiments. Cells were transfected with 2 lg of 3396 bp hTERT promoter reporter gene construct in the presence of various
amounts of AdCMV-p27 (0, 10, 25, 50, 100 m.o.i) (D). Luciferase activity was assessed 48 h after transfection and then normalized to b-gal activity.
Values are means ± S.D. from triplicate samples and are representative of two independent experiments.
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of expression vector encoding E2F-1 were co-transfected into
the cervical cancer cells. Transient expression of E2F-1 de-
creased luciferase activity in human cervical cancer cells,
HeLa, HT-3 (Fig. 4D) and Caski (data not shown). These
data suggest that E2F-1 inhibits hTERT expression in cervical
cancer cells in contrast to the expected results. Therefore it
can be concluded that the repression of hTERT expression
by p27 is not mediated by Rb/E2F-1. This was conﬁrmed
by testing whether or not the overexpressed p27 could repress
hTERT in the cells where the E2F activity was abolished by a
D/N E2F. Transiently transfected D/N E2F did not prevent
p27 mediated suppression of hTERT promoter activity (Fig.
4E). The transiently transfected Ad-p27 reduced the E7 pro-
tein level (Fig. 5A) but did not altered mRNA level in the
HeLa cells (Fig. 5B). It has been shown that E6 and E7 inac-
tivate p53 and Rb in human papillomavirus (HPV) positive
cells. E7 binds to p27 and the ability of E7 to arrest G0/G1
is mediated in part by binding to and subsequent inactivation
of p27. Therefore, the repression of E7 protein level by p27
might not be a general mechanism. Overexpressed E7 up-reg-
ulated hTERT promoter activity in HeLa and Caski cells
(Fig. 5C). We could not detect the change of E6 protein
and mRNA level by p27 overexpression. Taken together,
these results suggest that p27 down-regulates hTERT expres-
sion in cervical cancer and the suppression of E7 expression
may be a possible inhibitory pathway.3. Discussion
Telomerase activation is a key step in tumor progression.
Its constitutive activation is required for the catalytic sub-
unit, hTERT expression in most cases. Therefore, illuminat-
ing the regulatory mechanism of hTERT expression is of key
importance in understanding immortalization and tumorigen-
esis. Many oncogenes and tumor suppressor genes have been
implicated in regulating hTERT expression including p53,
SP1, c-Myc, Rb and E2F-1 [15–17,14]. In this study, we
found previously unknown p27-mediated telomerase regula-
tion. Overexpression of p27 suppressed the telomerase activ-
ity in cervical cancer cells. In addition, inhibition of
telomerase activity and hTERT mRNA expression by p27
correlated strongly with concomitant E7 expression, one of
the key events that up-regulate telomerase activity in HPV
positive cells.
p27 has been known as an inhibitor of the cyclin/CDK com-
plexes which block the G1-S transition. However, recent stud-
ies have proposed new functional roles of p27 as a key
modulator in tumor progression including apoptosis, diﬀeren-
tiation and cell–cell adhesion [8,9,18,19]. Our work demon-
strated that overexpression of p27 repressed hTERT mRNA
expression and telomerase activity in human cervical cancer
cell lines, which might be a novel tumor suppressive role of
p27. Furthermore, a signiﬁcantly higher basal level of hTERT
promoter activity of p27/ MEFs than that of WT MEFs
Fig. 3. Transcriptional activity of human telomerase promoter and eﬀect of p27 on telomerase activity in p27/ MEFs. (A) 3396 bp hTERT
promoter reporter gene construct (2 lg) was transfected into wild-type (WT) or p27/ primary embryonic ﬁbroblasts, then the basal level of
hTERT promoter activity was determined. (B) Cells were transfected with 2 lg of 3396 bp hTERT promoter reporter gene construct and various
amounts of AdCMV-p27 (0, 10, 25, 50, 100, 200 m.o.i). (C) AdCMV-p27 (100 m.o.i.) was transiently transfected into p27/ primary embryonic
ﬁbroblasts for the indicated times. (D) p27/ primary embryonic ﬁbroblasts cells were cultured in the presence of IFN-c (250 U/ml) for the
indicated times. Telomerase activity was determined using TRAP assay. Luciferase activity was assessed 48 h after transfection and then normalized
to b-gal activity. Values are means ± S.D. from triplicate samples and are representative of two independent experiments.
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regulators of hTERT promoter. Our results showed the resid-
ual hTERT promoter activity in p27 knock-out MEFs and
incomplete shut oﬀ promoter activity by p27 overexpression.
These results suggest that other proteins may also participate
in regulating the hTERT promoter activity.
In many cases, p27 is regulated at the level of post-transcrip-
tion by ubiquitin/proteasome pathway [20–22]. Here we pro-
pose a novel IFN-c/IRF-1 signaling pathway that represses
hTERT expression and telomerase activity possibly via the
down-regulation of HPV E7 protein level. As expected, p27
was post-transcriptionally up-regulated by IFN/IRF-1 signal-
ing. Binding of HPV E7 protein has been proposed as a poten-
tial mechanism inactivating p27 [23]. Therefore, the induction
of p27 level may be due to the abrogation of E7 protein. Inter-
estingly, we found that p27 down-regulated E7 protein expres-
sion (we could not detect E6 protein expression) in the HPV
positive cell, HeLa. We also observed that transiently tran-
fected E6 and E7 activate the hTERT promoter. It was con-
cluded that p27 down-regulates hTERT promoter activity, at
least in part, by inhibiting E7 protein expression.
Deregulation of p27 has been implicated as a reliable
prognostic indicator for many human malignancies [24,25].Mice deﬁcient in p27 exhibit increased susceptibility to
tumor progression and tumorigenecity is accelerated in
Rb+/p27/ and p18INK4c/p27/ mice [11,26] sug-
gesting that p27Kip-1 is a rate-limiting factor for tumorigen-
esis. This tumor suppressive role of p27 might be due to the
enhanced apoptosis, even though anti-apoptotic eﬀects of
p27 were also reported. Several groups have suggested a pos-
sible relationship between the telomerase activity and p27 in
diﬀerentiating tumor cells or anti-cancer agents treated or
irradiated tumor cells [6,27,28]. However, no direct evidence
was provided. This work is the ﬁrst report showing direct
evidence of the eﬀects of p27 protein on hTERT expression
using both human cervical cancer cells and primary MEFs
deﬁcient in p27.
Hyperphosphorylated, inactive Rb releases E2F-1 which
can either be a transcriptional activator or repressor of
hTERT gene. A number of studies have suggested that
E2F-1 might act as a transcriptional repressor when it is
bound by Rb [29,30]. The results in this study showed that
p27 inhibited the phosphorylation of Rb but overexpressed
E2F-1 unexpectly suppressed hTERT expression in cervical
cancer cells. Transiently transfected D/N E2F did not change
p27 mediated suppression of hTERT promoter activity.
Fig. 4. Eﬀect of IFN-c or p27 on the expression of cyclin/CDKs or pRb each other in HeLa and HT-3 cells. Western blot analysis was performed on
total cell lysates (20 lg) using anti-serum against represented protein products after IFN-c treatment (A). Lysates were prepared from cells treated
with IFN-c and subjected to immunoprecipitation using anti-CDK2 antibody. Immunoprecipitates were used to perform in vitro phosphorylation
assays with histon H1 as substrate (B). AdCMV-p27 was transiently transfected into each cell lines and Western blot analysis was performed for the
indicated time (C). Luciferase activity was assessed 48 h after pcDNA3.1-E2F1 transfection and then normalized to b-gal activity (D). Eﬀect of D/N
E2F on hTERT promoter activity was assessed 48 h after AdCMV-p27 transfection (E). Cells were transfected with various amount of pcDNA3.1-
E2F(D/N) (0, 1, 2, 5 lg). Values are means ± S.D. from triplicate samples and are representative of two independent experiments. *P < 0.05,
**P < 0.01 compared to control.
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pression of hTERT expression or telomerase activity by
p27 in cervical cancer cells.
In conclusion, this study provides evidence showing p27 to
be a negative regulator of hTERT expression and telomerase
activity. Telomerase repression might be mediated by E7
expression in human HPV positive cervical cancer but not
via the Rb–E2F pathway. This suggests a novel functional role
of p27 in tumor suppression and that p27 might be a potent
anti-tumor therapeutic agent.4. Materials and methods
4.1. Cell culture and mice
HeLa and HT-3 are human cervical cancer cell lines. HeLa is a HPV
E6/E7 positive cell line and HT-3 is a HPV E6/E7 negative cell line in
which p53 and Rb are mutated. These cells were maintained in Dul-
beccos modiﬁed Eagles medium (DMEM) supplemented with 10% fe-
tal calf serum (Life Technologies Inc., Gaithersburg, MD), Fungizon
(Life Technologies), anti-PPLO (Life Technologies), streptomycin,
and penicillin G at 37 C with humidiﬁed atmosphere of 5% CO2.
All mice were housed in cages with ﬁlter tops in a laminar-ﬂow hood,
fed food and acid water ad libitum, and bred in a SPF facility. Mice
Fig. 5. Eﬀects of p27 on the expression of E7 and eﬀect of E6/E7 on hTERT promoter activity. p27 eﬀect on E7 expression were performed by
Western hybridization (A) and RT-PCR analysis (B). Cells were transfected with 2 lg of human telomerase 3396 bp promoter reporter gene construct
and 2 lg of expression vector, pcDNA3.1-E6 or -E7. The E6 and E7 expressing pcDNAs were transfected into HeLa cells and the expression was
conﬁrmed by Western hybridization (C). Luciferase activity was assessed 48 h after transfection and then normalized to b-gal activity. Values are
means ± S.D. from triplicate samples and are representative of two independent experiments. *P < 0.05, **P < 0.01 compared to control.
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The Jackson Lab) gene had been backcrossed to C57BL/6 seven to
ten times. Primary MEFs from IRF-1-deﬁcient mice were prepared
from embryos at the day 13.5 of development (E13.5), and cultured
in DMEM with 10% FBS.
4.2. Plasmids and cell transfections
Human telomerase 3996 bp promoter subcloned into pGL3-luc
(Promega, USA) was provided by Kim [29]. D/N E2F construct was
provided by Saunders [31]. MEFs were used at early passage (3–5 pas-
sage) for transfection in 6-well plates. MEF transfection experiments
were carried out using Eﬀectene (Qiagen) according to the manufac-
turers instructions. A SV40-pRL (Promega) was co-transfected to nor-
malize the transfection eﬃciency.
4.3. Construction of adenovirus expressing p27
A full-length cDNA of p27 was prepared by PCR using the 5 0-AAG
ATGTCAAACGTGCGAG and 3 0-TTACGTTTGACGTCTTCTG
primers. Then cloned into pCR2.1-TOPO vector (Invitorgen, Carls-
bad, CA) and sequenced thoroughly to ensure their integrity.
pDACMV-p27 was generated by the insertion of EcoRI fragment of
veriﬁed p27 gene into pDACMVp(A). pDACMV-p27 and adenovirus
backbone vector, pJM17, were co-transfected into the packaging cell
line, 293 using Fugene 6 transfection reagent (Boehringer–Mannheim).
The titer of the virus stock was determined by plaque assay on lawns of
293 cells. AdCMV-b gal was used as an internal control.
4.4. RT-PCR analysis of hTERT mRNA
Expression of hTERT mRNA was analyzed by RT-PCR ampliﬁca-
tion. Total RNA was prepared from cell lines using TRIsol (Gibco-
BRL) according to the manufacturers protocol. One lg of total
RNA was reverse transcribed at 37 C for 45 min in the presence of
random hexamers and Moloney murine leukemia virus reverse trans-
criptase (Gibco-BRL). Analysis of the expression of the telomerase
subunit was performed by RT-PCR ampliﬁcation as described previ-ously [32]. The 145-bp hTERT fragment was ampliﬁed using the pri-
mer pair 5 0-CGG-AAG-AGT-GTC-TGG-AGC-AA-30 and 5 0-GGA-
TGA-AGC-GGA-GTC- TGG-A-3 0.
4.5. Telomerase assay
Extracts from cell lines and cervical cancer tissues were prepared by
CHAPS lysis buﬀer. Telomerase activity was detected by TRAPEZE
Telomerase Detection Kit (Intergen Co.) according to the manufac-
turers protocol. Telomerase activity was calculated by computing
the ratio of the entire ladder to the signal of the ampliﬁed internal con-
trol. We used 0.5 lg protein extract for each sample and a 36-bp inter-
nal standard was used as an internal control.
4.6. Luciferase assay
Transient transfection of luciferase reporter plasmids was performed
using LipofectAMINE (Life Technologies) according to the manufac-
turers protocol. Luciferase assays were performed using the standard
luciferase assay system (Promega). All experiments were performed in
triplicate.
4.7. Western blot analysis
Cells were lysed and equal amounts of cell extracts (20 lg) were elec-
trophoresed on 12% SDS–polyacrylamide gel, electrotransferred onto
a nitrocellulose membrane, and probed with antibodies. The antibod-
ies for IRF-1, p27, cyclin A, HPV type 18 E7, pRb were purchased
from Santa Cruz Biotechnology, Inc.; cyclin E and CDK2 were from
Neomarkers (CA, USA) and HPV type 18 E6 was from Chemicon
(CA, USA). Detection was performed using the enhanced chemilumi-
nescence system (Amersham).
4.8. Kinase assay of CDK2
Lysates were prepared fromHeLa andHT-3 cells treated with IFN-c.
CDK2 antisera (Neomarkers, CA) were used to isolate CDK2-contain-
ing complexes. Complexes were resuspended in 1· kinase reaction
buﬀer containing 10 lCi of [c-32P]ATP, 10 lM ATP and histon H1
S.-H. Lee et al. / FEBS Letters 579 (2005) 1027–1033 1033and incubated for 30 min at 30 C. The ability of immunocomplexed
proteins to phosphorylate histon H1 in in vitro kinase assays was mea-
sured by autoradiography.References
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